Immunity challenge

Rybka, Ted
June 2005
Echo Magazine;6/2/2005, Vol. 16 Issue 19, p53
Interviews Doctor Jon Kaiser about AIDS. Effectiveness of his HIV/AIDS treatment plan; Changes in the development and treatment of HIV and AIDS; Views on the efficiency of the combination of vitamin supplements and antiviral therapy in treating HIV and AIDS.


Related Articles

  • Oral status of HIV‐infected children aged 12 years or younger who attended a Paediatric Infectious Diseases Clinic in Cape Town. Mohamed, Nadia; Mathiba, Olorato Patience; Mulder, Riaan // Clinical & Experimental Dental Research;Feb2020, Vol. 6 Issue 1, p75 

    Background: Children continue to suffer from the impact of the human immunodeficiency virus‐acquired immunodeficiency syndrome (HIV/AIDS) pandemic. In Cape Town, these children receive medical care including antiretroviral therapy from facilities like Tygerberg Hospital's Paediatric...

  • Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. Mojumdar, Kamalika; Vajpayee, Madhu; Chauhan, Neeraj K.; Mendiratta, Sanjay // BMC Public Health;2010, Vol. 10 Issue 1, p416 

    Background: Timely access to antiretroviral therapy is a key to controlling HIV infection. Late diagnosis and presentation to care diminish the benefits of antiretrovirals and increase risk of transmission. We aimed to identify late presenters in patients sent for first CD4 T cell count after...

  • "Driving the devil away": qualitative insights into miraculous cures for AIDS in a rural Tanzanian ward. Roura, Maria; Nsigaye, Ray; Nhandi, Benjamin; Wamoyi, Joyce; Busza, Joanna; Urassa, Mark; Todd, Jim; Zaba, Basia // BMC Public Health;2010, Vol. 10 Issue 1, p427 

    Background: The role of religious beliefs in the prevention of HIV and attitudes towards the infected has received considerable attention. However, little research has been conducted on Faith Leaders' (FLs) perceptions of antiretroviral therapy (ART) in the developing world. This...

  • Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. Dahab, Mison; Charalambous, Salome; Karstaedt, Alan S.; Fielding, Katherine L.; Hamilton, Robin; La Grange, Lettie; Churchyard, Gavin J.; Grant, Alison D. // BMC Public Health;2010, Vol. 10 Issue 1, p430 

    Background: Many national antiretroviral therapy (ART) programmes encourage providers to identify and address baseline factors associated with poor treatment outcomes, including modifiable adherence-related behaviours, before initiating ART. However, evidence on such predictors is scarce, and...

  • Perspectives on HAART: switch maintenance therapy. Leen, C. L. S. // International Journal of STD & AIDS;Sep2003, Vol. 14 Issue 9, p577 

    Switch studies have been carried out to explore changes in side effects in adherence. Discontinuing the protease inhibitor (PI) component of highly active antiretroviral therapy (HAART) regimen is often associated with improved adherence and improved quality of life. Following switching from a...

  • HIV-1 Protease: Structural Perspectives on Drug Resistance. Weber, Irene T.; Agniswamy, Johnson // Viruses (1999-4915);Dec2009, Vol. 1 Issue 3, p1110 

    Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms of drug resistance and guided the design...

  • Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Zhiqing Zhang; Shaowei Li; Ying Gu; Ningshao Xia // International Journal of Molecular Sciences;Nov2016, Vol. 17 Issue 11, p1901 

    Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is primarily controlled through antiretroviral therapy (ART) but this treatment does not cure HIV-1 infection. Furthermore,...

  • Enfuvirtide Added to an Optimized Antiretroviral Regimen Provided Significant Benefits in Patients with Multidrug-Resistant HIV Infection. Lorber, Bennett // Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p877 

    The article presents information on papers related to infectious diseases in the U.S. The paper "Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America," by J.P. Lalezari, K. Henry, M. O'Hearn et al. studied that enfuvirtide added to an optimized...

  • AIDS Meds Take Center Stage in South Africa. Houlton, Sarah // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p26 

    Reports on the annual spending of South Africa on antiretroviral medicines for AIDS. Provision of drugs by the African government for free; Impact of the AIDS problem on the annual gross domestic product of the country; Availability of the medicines.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics